Forte Biosciences (FBRX) Profit After Tax (2016 - 2026)

Forte Biosciences (FBRX) has reported Profit After Tax for 11 consecutive years, with -$22.1 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Profit After Tax fell 41.39% year-over-year to -$22.1 million; the TTM figure through Mar 2026 stood at -$75.8 million (down 73.5% YoY), while the FY2025 annual figure was -$69.4 million, down 95.54% from the prior year.
• Profit After Tax grew to -$22.1 million in Q1 2026 per FBRX's latest filing, from -$24.8 million in the prior quarter.
• Across five years, Profit After Tax topped out at -$2.6 million in Q1 2022 and bottomed at -$24.8 million in Q4 2025.
• Historically, Profit After Tax has averaged -$10.1 million across 5 years, with a median of -$8.4 million in 2024.
• Annual changes were most pronounced in 2022 — Profit After Tax soared 56.13% — and 2025, when it sank 246.35%.
• Forte Biosciences' Profit After Tax stood at -$4.9 million in 2022, then slipped by 20.4% to -$5.9 million in 2023, then decreased by 21.8% to -$7.2 million in 2024, then tumbled by 246.35% to -$24.8 million in 2025, then rose by 10.64% to -$22.1 million in 2026.
• Business Quant data shows FBRX's Profit After Tax at -$22.1 million in Q1 2026, -$24.8 million in Q4 2025, and -$17.7 million in Q3 2025.